LTE- Safety, Tolerability and Efficacy of TAK-279
Research type
Research Study
Full title
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
IRAS ID
1013556
Contact name
Casey Howe
Contact email
Sponsor organisation
Takeda Development Center Americas Inc.
Clinicaltrials.gov Identifier
Research summary
Psoriatic arthritis (PsA) is a long-term condition that affects the skin and joints. Arthritis causes pain and swelling (inflammation) in the joints. Psoriasis is a condition where red, scaly patches appear on the skin. PsA is an autoimmune condition which means the body’s germ fighting (immune) system mistakenly attacks the healthy cells in the joints and skin. Common symptoms of PsA include joint pain in arms, legs, hands, feet, and spine, stiffness in the joints, swollen fingers and toes, and abnormal skin and nail appearance. This condition can also affect the body’s movements. Zasocitinib, also called TAK-279, is a medicine that is taken by mouth (orally), which may reduce inflammation in PsA.
Adults who completed the 1-year (52-week) treatment period in one of the parent studies (either TAK-279-PsA-3001 or TAK-279-PsA-3002) may be able to continue treatment with zasocitinib in this continuation study (also called long-term extension or LTE study). The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with active PsA over a longer period of time.
Treatment is given once a day for up to 2 years (104 weeks). Throughout the study, blood samples will be taken for laboratory tests to monitor the health of participants.REC name
London - Westminster Research Ethics Committee
REC reference
26/LO/0260
Date of REC Opinion
30 Apr 2026
REC opinion
Further Information Favourable Opinion